SecBot SecBot
SECBOTREPLAY Home › Report › GSK

GSK · In the long-running Lamictal reverse-payment antitrust case, the…

GSK plc · COURT-RULING filed Mar 30, 2026 at 20:00 ET

At the news

NEUTRALIMPACT 3/10

COURT-RULING filed Mar 30, 2026 at 20:00 ET

In the long-running Lamictal reverse-payment antitrust case, the District Court for the District of New Jersey vacated a magistrate's order that had permitted five new expert reports from GSK and Teva without reviewing their content. The court found the magistrate's decision clearly erroneous and remanded for further proceedings, requiring the magistrate to assess whether the reports were within the scope of the scheduling order. This procedural setback for GSK increases uncertainty but does not resolve the underlying antitrust claims.

  • District court vacated magistrate's order allowing new expert reports without content review
  • Case involves allegations of illegal reverse-payment settlement to delay generic Lamictal
  • Matter remanded to magistrate for further proceedings to determine if reports comply with scheduling order

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access